168 related articles for article (PubMed ID: 37975609)
1. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
2. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
[TBL] [Abstract][Full Text] [Related]
3. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
[TBL] [Abstract][Full Text] [Related]
4. Comparing high-dose dual therapy with bismuth-containing quadruple therapy for the initial eradication of Helicobacter pylori infection on Hainan Island: A randomized, multicenter clinical trial.
Liu DN; Wang QY; Li PY; Wu DH; Pan J; Chen ZY; Li YQ; Han XY; Lan C; Tang J; Tan Y; Mo CY; Yang WZ; Han JL; Huang XX
Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102125. PubMed ID: 37062356
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
6. Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Tungtrongchitr N; Bongkotvirawan P; Ratana-Amornpin S; Siramolpiwat S; Eiamsitrakoon T; Gamnarai P; Wongcha-Um A; Yamaoka Y; Pawa KK; Vilaichone RK
Sci Rep; 2024 Apr; 14(1):8986. PubMed ID: 38637591
[TBL] [Abstract][Full Text] [Related]
7. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China.
Hu J; Mei H; Su NY; Sun WJ; Zhang DK; Fan LL; He P; Pan J; Wang XW; Zou PY; Liu YX; Guo Y; Lan CH
Helicobacter; 2023 Aug; 28(4):e12970. PubMed ID: 37160689
[TBL] [Abstract][Full Text] [Related]
8. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
[TBL] [Abstract][Full Text] [Related]
9. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
10. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: An open-label, multicenter, randomized controlled trial.
Guan JL; Hu YL; An P; He Q; Long H; Zhou L; Chen ZF; Xiong JG; Wu SS; Ding XW; Luo HS; Li PY
Pharmacotherapy; 2022 Mar; 42(3):224-232. PubMed ID: 35075679
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG; Jiang X; Ding YB; She Q; Li YY
Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Vonoprazan-Amoxicillin Dual Regimen With Varying Dose and Duration for Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Study.
Peng X; Yao JY; Ma YQ; Li GH; Chen HW; Wan Y; Liang DS; Zhang M; Zhi M
Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1210-1216. PubMed ID: 38309492
[TBL] [Abstract][Full Text] [Related]
14. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line
Suzuki S; Gotoda T; Kusano C; Ikehara H; Ichijima R; Ohyauchi M; Ito H; Kawamura M; Ogata Y; Ohtaka M; Nakahara M; Kawabe K
Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
Gotoda T; Kusano C; Suzuki S; Horii T; Ichijima R; Ikehara H
J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
[TBL] [Abstract][Full Text] [Related]
17. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
[TBL] [Abstract][Full Text] [Related]
18. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
[TBL] [Abstract][Full Text] [Related]
19. Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.
Han YY; Zhou L; Hu YL; Ding XW; Long H; Liu F; Xu M; Zhang ZY; Li SL; Wang QY; Su CX; Chen Y; Chen J; Lin Y; Li PY
J Gastroenterol; 2023 Dec; 58(12):1167-1177. PubMed ID: 37777987
[TBL] [Abstract][Full Text] [Related]
20. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
